A carregar...
Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program
OBJECTIVE: Tofacitinib is an oral JAK inhibitor indicated for the treatment of rheumatoid arthritis (RA). We characterized lymphoma events in the tofacitinib RA clinical development program. METHODS: Lymphoma events (up to March 2015) were identified from 19 tofacitinib studies (2 phase I, 9 phase I...
Na minha lista:
| Publicado no: | Arthritis Care Res (Hoboken) |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5947561/ https://ncbi.nlm.nih.gov/pubmed/28941219 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acr.23421 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|